Nuvilex, Inc. (OTCQB: NVLX) announced today substantial testing has been completed and more testing is underway combining its patented encapsulation technology with live stem cells. The testing was carried out in SG Austria’s laboratories in Singapore. The uniqueness of our encapsulation process allows us to produce vast quantities of live virgin stem cells that can be used for many applications in aiding research and in a variety of clinical therapeutic applications and treatments.
In combining our encapsulation technology with live stem cells, we are able to place the encapsulated live stem cells into specific locations or organs in the body. Because the live stem cells are encapsulated, the cells will adapt themselves to the new environment and begin to change without migrating away from their location. This will in turn cause nearby cells to receive specific signals that aid in the potential remodeling or repairing of a damaged organ. Being able to maintain the cells in a specific site or organ where they have been placed allows for greater treatment efficacy without losing live stem cells migrating from the insertion site.
Dr. Robert Ryan, President and CEO of Nuvilex, stated, “This cutting edge technology and potential use of live stem cells is one of the reasons why SG Austria and our technology provide a tremendous growth and revenue opportunity for Nuvilex. The ability to expand live stem cells in large numbers, in their virgin state without changing their properties, is unique and only the first step in the evolving use of live stem cells. It will enable Nuvilex to broaden the use of this technology by offering our services to major pharmaceutical companies throughout the United States and abroad. This market potential combined with early results of the clinical use of live stem cells indicates their extremely impressive and encouraging value for the future of medicine and Nuvilex shareholders.”
Nuvilex, Inc. (OTCQB:NVLX) is an innovative biotechnology and natural products company whose oncology offerings include cancer treatment using the company’s industry-leading live-cell encapsulation technology. Current natural products include BiaDiagnostics certified Gluten-Free Cinnergen™, 3 oz. travel size Cinnergen™, Cinnechol™ and others to enhance a healthy lifestyle, cosmetic use, flu treatment, tattoo inks, antimicrobial and antinematodal agents.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.Business Wire
Last updated on: 10/10/2011
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.